ArticleMicroorganisms2022
Comparative Genomics and Physiology of
Article in Microorganisms, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
16 citing papers in PubMed, 15 citations in OpenAlex.
- Pasteurized Akkermansia muciniphila MucNature medicine · 2026Trial
- Mechanism and application ofFrontiers in cellular and infection microbiology · 2026Review
- Probiotic Engraftment of Akkermansia muciniphila in an In Vitro Synthetic Microbial Community.Microbial ecology · 2025Article
- The Biology ofAnnual review of microbiology · 2025Review
- The genus Akkermansia is populated by a multitude of biological species with a wide distribution in the animal kingdom.Biology direct · 2025Article
- Akkermansia muciniphila: promises and pitfallsfor next-generation beneficial microorganisms.Archives of microbiology · 2025Review
- Akkermansia muciniphila: biology, microbial ecology, host interactions and therapeutic potential.Nature reviews. Microbiology · 2025Review
- Metagenomic Studies Reveal the Evidence of Akkermansia muciniphila and Other Probiotic Bacteria in the Gut of Healthy and Enterocytozoon hepatopenaei (EHP)-Infected Farmed Penaeus vannamei.Probiotics and antimicrobial proteins · 2025Article
- Health Effects and Therapeutic Potential of the Gut MicrobeNutrients · 2025Review
- Enhanced metagenomic strategies for elucidating the complexities of gut microbiota: a review.Frontiers in microbiology · 2025Review
- Review
- Binding of Akkermansia muciniphila to mucin is O-glycan specific.Nature communications · 2024Article
- Function and therapeutic prospects of next-generation probioticFrontiers in microbiology · 2024Review
- Analysis of gut microbiota in patients with Williams-Beuren Syndrome reveals dysbiosis linked to clinical manifestations.Scientific reports · 2023Article
- Insights into early evolutionary adaptations of theFrontiers in microbiology · 2023Article
- Characterization of antibiotic-resistance traits in Akkermansia muciniphila strains of human origin.Scientific reports · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 6 institutions in 6 countries.
Funding
Abstract
Akkermansia muciniphila is a champion of mucin degradation in the human gastrointestinal tract. Here, we report the isolation of six novel strains from healthy human donors and their genomic, proteomic and physiological characterization in comparison to the type-strains A. muciniphila MucT and A. glycaniphila PytT. Complete genome sequencing revealed that, despite their large genomic similarity (>97.6%), the novel isolates clustered into two distinct subspecies of A. muciniphila: Amuc1, which includes the type-strain MucT, and AmucU, a cluster of unassigned strains that have not yet been well characterized. CRISPR analysis showed all strains to be unique and confirmed that single healthy subjects can carry more than one A. muciniphila strain. Mucin degradation pathways were strongly conserved amongst all isolates, illustrating the exemplary niche adaptation of A. muciniphila to the mucin interface. This was confirmed by analysis of the predicted glycoside hydrolase profiles and supported by comparing the proteomes of A. muciniphila strain H2, belonging to the AmucU cluster, to MucT and A. glycaniphila PytT (including 610 and 727 proteins, respectively). While some intrinsic resistance was observed among the A. muciniphila straind, none of these seem to pose strain-specific risks in terms of their antibiotic resistance patterns nor a significant risk for the horizontal transfer of antibiotic resistance determinants, opening the way to apply the type-strain MucT or these new A. muciniphila strains as next generation beneficial microbes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.